Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07095205
PHASE4

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

Sponsor: Stony Brook University

View on ClinicalTrials.gov

Summary

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Official title: Central Cholinergic Dysfunction in Depression: PET Imaging of a Novel Treatment Target With [18F]VAT to Assess the Antidepressant Effect of Nicotine

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

14

Start Date

2024-10-03

Completion Date

2029-09-30

Last Updated

2025-07-31

Healthy Volunteers

Yes

Interventions

DRUG

Nicotine transdermal patch

The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).

DRUG

PET Scan with [18F] VAT

All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Locations (1)

Stony Brook University: Dept of Psychiatry

Stony Brook, New York, United States